REG-Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update
Globe Newswire•11/11/2026•16:15 ET
0
Key Highlights
- ➤Adjusted revenue $323.4M, down 23.0% year over year
- ➤Adjusted EBITDA $78.3M, up 15.1% year over year
- ➤2026 revenue and EBITDA guidance maintained, toward lower ends
- ➤Cash balance fell to $61.5M from $172.4M at 2025-end
- ➤FDA approved Simlandi manufacturing changes, more than doubling batch output
Expert Statements
Lisa Graver, Chief Executive Officer of Alvotech
“Our commercial performance strengthened in the third quarter, with product and service revenue reaching $58 million, up 6% sequentially and 78% year over year. Following the completion of the manufacturing improvement program in the first half of the year, we are continuing to increase supply to meet strong underlying demand across our markets.”
Lisa Graver, Chief Executive Officer of Alvotech
“The two recent FDA approvals for Simlandi at our Reykjavík facility represent significant milestones. The addition of a second approved manufacturing suite and an enhanced process that more than doubles output per batch give us greater capacity and operational flexibility to support our expanding commercial portfolio.”
Lisa Graver, Chief Executive Officer of Alvotech
“We have also made important advances in our pipeline, including regulatory milestones for our proposed biosimilars to Entyvio and high-dose Eylea. Our agreement with Lotus creates an opportunity for Alvotech to participate directly in U.S. commercialization, while our partnerships with LOTTE Biologics and Fujifilm strengthen our future manufacturing network. Our priority now is to translate this progress into planned product deliveries in the fourth quarter, while continuing to build the platform for long-term growth.”
REYKJAVIK, ICELAND (November 11, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the nine months to September 30, 2026, and provided a business update.
Supplemental information, including the management presentation providing additional details and a business update, is available on our website: https://alvotech.com/financials.(1)
Get started
Create a free account to read the full story.